Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19013003 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18893805 | TREATMENT OF DIABETIC RETINOPATHY WITH OPHTHALMIC COMPOSITIONS | September 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18893796 | STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18893790 | TREATMENT OF OCULAR INFLAMMATION FOLLOWING OCULAR SURGERY | September 2024 | May 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18893806 | PH STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18893810 | PH STABILIZED OPHTHALMIC COMPOSITIONS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18816200 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18797696 | Mycophenolate Oral Suspension | August 2024 | November 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18797717 | Mycophenolate Oral Suspension | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18664253 | SURGICAL REPAIR GRAFT | May 2024 | May 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18653190 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18703772 | SKIN BARRIER PROTECTIVE DELIVERY SYSTEMS | April 2024 | September 2024 | Allow | 4 | 1 | 0 | No | No |
| 18703841 | SKIN BARRIER PROTECTIVE DELIVERY SYSTEMS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18703824 | APIXABAN SUSPENSION AND PREPARATION METHOD | April 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18629986 | DISSOLVING MICRONEEDLE CONTAINING CANNABIDIOL SUSPENSION AND PREPARATION METHOD THEREOF | April 2024 | August 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18628237 | TOPICAL COMPOSITIONS COMPRISING EMULSIFIED POVIDONE IODINE SOLUTIONS AND METHODS OF PREPARATION | April 2024 | June 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18605258 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS | March 2024 | June 2025 | Allow | 15 | 1 | 0 | No | No |
| 18442802 | Mycophenolate Oral Suspension | February 2024 | July 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18442765 | Mycophenolate Oral Suspension | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18434065 | SUSTAINED RELEASE MELATONIN COMPOSITIONS | February 2024 | July 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18545896 | COMPOSITION FOR TREATING NIGHT BLINDNESS | December 2023 | August 2024 | Allow | 7 | 2 | 0 | No | No |
| 18534301 | SELF-EMULSIFYING CANNABIDIOL FORMULATIONS | December 2023 | January 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18518202 | PHARMACEUTICAL COMPOSTION CONTAINING ACETOMINOPHEN AND IBUPROFEN | November 2023 | September 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18445610 | Method of Arthropod Egress | November 2023 | November 2024 | Allow | 12 | 3 | 0 | No | No |
| 18498661 | Devices and Methods for Delivering Methane Inhibiting Compounds to Animals | October 2023 | June 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18384000 | TREATMENT OF DIABETIC RETINOPATHY | October 2023 | May 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18383991 | STABILIZED DEXAMETHASONE COMPOSITIONS | October 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18383993 | TREATMENT OF OCULAR INFLAMMATION | October 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18380472 | FLOWABLE ACELLULAR TISSUE MATRIX PRODUCTS AND METHODS OF PRODUCTION | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18378069 | TOPICAL COMPOSITIONS COMPRISING EMULSIFIED POVIDONE IODINE SOLUTIONS AND METHODS OF PREPARATION | October 2023 | February 2024 | Allow | 5 | 1 | 0 | No | No |
| 18553911 | LYOPHILIZED COMPOSITION OF COPANLISIB SALT | October 2023 | August 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18372165 | CONTROLLED DRUG RELEASE FROM ELECTROSPUN FIBERS | September 2023 | September 2024 | Allow | 12 | 1 | 0 | No | No |
| 18472426 | DRUG DELIVERY SYSTEMS | September 2023 | October 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18371163 | FILM-FORMING COMPOSITION CONTAINING SURFACTANT OR SURFACTANT AND SALT AS WHITENING AGENT | September 2023 | March 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18369241 | ABUSE AND MISUSE DETERRENT TRANSDERMAL SYSTEMS | September 2023 | January 2025 | Allow | 16 | 1 | 0 | No | No |
| 18369754 | Oral Dosage Forms Comprising a Hops Extract | September 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18448990 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC PAIN AND DEPRESSION | August 2023 | February 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18362179 | PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE | July 2023 | February 2024 | Allow | 6 | 2 | 0 | No | No |
| 18359685 | N-ACETYLCYSTEINE COMPOSITIONS AND METHODS | July 2023 | June 2024 | Allow | 10 | 1 | 0 | No | No |
| 18352356 | KOMBUCHA NATURAL HEALTH PRODUCTS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18214770 | PHARMACEUTICAL COMPOSITIONS COMPRISING ISOTRETINOIN AND PROCESSES FOR PREPARATION AND USES THEREOF | June 2023 | February 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18339267 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | June 2023 | February 2024 | Allow | 8 | 1 | 0 | No | No |
| 18323101 | PHARMACEUTICAL COMPOSITION COMPRISING ADRENALINE | May 2023 | February 2024 | Allow | 9 | 2 | 0 | No | No |
| 18200828 | MELT PROCESSED VIRAL NANOPARTICLE CONSTRUCTS | May 2023 | July 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18316850 | COMPOSITION COMPRISING HIGHLY-CONCENTRATED ALPHA1 PROTEINASE INHIBITOR AND METHOD FOR OBTAINING THEREOF | May 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18141357 | EXTRACT OF AGATHIS ROBUSTA AS ANTIFUNGAL AGENT | April 2023 | December 2023 | Allow | 7 | 2 | 0 | No | No |
| 18301072 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18190372 | Method for Preparing High-load Oral Paclitaxel Capsule for Slow Release in Colon | March 2023 | August 2023 | Allow | 4 | 1 | 0 | No | No |
| 18126251 | METHODS OF TREATMENT USING CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS | March 2023 | February 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18126138 | WHIPPED FORMULATIONS | March 2023 | July 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18124462 | BLEND COMPOSITIONS FOR ORAL ADMINISTRATION AS A RAPIDLY DISSOLVING POWDER AND/OR SUSPENSION | March 2023 | February 2024 | Allow | 10 | 1 | 0 | No | No |
| 18124291 | WHIPPED FORMULATIONS | March 2023 | April 2024 | Abandon | 13 | 1 | 0 | Yes | No |
| 18123292 | MICRONEEDLE ARRAY WITH ACTIVE INGREDIENT | March 2023 | July 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18120054 | Solid Forms and Methods of Preparing the Same | March 2023 | August 2024 | Allow | 18 | 1 | 0 | No | No |
| 18114304 | IMPLANTABLE NANOCHANNEL DELIVERY DEVICES | February 2023 | July 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18157653 | SURGICAL REPAIR GRAFT | January 2023 | February 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18154524 | STABLE PILOCARPINE FORMULATIONS WITH MODIFIED BUFFER CHARACTERISTICS AND RELATED METHODS | January 2023 | August 2023 | Allow | 7 | 1 | 0 | No | No |
| 18150590 | CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAME | January 2023 | March 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18088375 | LIQUID PHARMACEUTICAL FORMULATIONS OF TAFAMIDIS | December 2022 | March 2024 | Allow | 15 | 3 | 0 | Yes | No |
| 18087128 | POWDERED COLLAGEN WOUND CARE COMPOSITIONS | December 2022 | August 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 18087608 | PHARMACEUTICAL COMPOSTION CONTAINING ACETOMINOPHEN AND IBUPROFEN | December 2022 | October 2023 | Allow | 9 | 1 | 0 | No | No |
| 18083977 | NICOTINE POUCH | December 2022 | July 2023 | Allow | 7 | 1 | 0 | No | No |
| 18066196 | COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL FUNCTION | December 2022 | June 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 18009298 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | December 2022 | September 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 18058463 | Extract containing oleandrin and method of production thereof | November 2022 | March 2024 | Allow | 16 | 3 | 1 | No | No |
| 18055388 | KAOLINITE COMPOSITE DIAGNOSTIC AND THERAPEUTIC AGENT AND PREPARATION METHOD AND USE THEREOF | November 2022 | September 2023 | Allow | 10 | 1 | 0 | No | No |
| 17961690 | COMPOSITIONS FOR PREVENTION OF SIDE EFFECTS RELATED TO ALCOHOL CONSUMPTION | October 2022 | April 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17960817 | THERAPEUTIC PREPARATION OF ACTIVATED ST. JOHN'S WORT | October 2022 | December 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17943356 | MAGNETIC DRESSING AND PREPARATION METHOD AND USE THEREOF | September 2022 | December 2023 | Allow | 15 | 2 | 0 | Yes | No |
| 17817731 | CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE | August 2022 | October 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17879041 | CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE | August 2022 | October 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17871058 | CALCIUM GLUCONATE FORMULATION WITHOUT CALCIUM SACCHARATE | July 2022 | January 2023 | Allow | 6 | 1 | 0 | No | No |
| 17869482 | Methods of Treating Skin Diseases | July 2022 | December 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17811972 | DEEP PENETRATING TOPICAL CANNABINOID COMPOSITIONS AND METHODS FOR TREATING MUSCULOSKELETAL INFLAMMATION AND PAIN | July 2022 | April 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 17858405 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM | July 2022 | October 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17857587 | N-ACETYLCYSTEINE COMPOSITIONS AND METHODS | July 2022 | April 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17789098 | COMPOSITION FOR REMINERALIZING TOOTH ENAMEL | June 2022 | July 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17848290 | SALINE-BASED COMPOSITION FOR PIERCING AFTERCARE | June 2022 | April 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17842339 | SODIUM HYPOCHLORITE AND CHLORHEXIDINE BASED NANOEMULSIONS AND A METHOD OF PREPARATION THEREOF | June 2022 | August 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17840829 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | June 2022 | March 2023 | Allow | 9 | 2 | 1 | No | No |
| 17805967 | Fast Dispersing Suspending Composition, Method of Preparation And Application Thereof | June 2022 | February 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17834006 | NICOTINE POUCH | June 2022 | September 2022 | Allow | 3 | 1 | 0 | Yes | No |
| 17828129 | KOMBUCHA NATURAL HEALTH PRODUCTS | May 2022 | April 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17727442 | HAIR LOTION | April 2022 | December 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17724045 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS | April 2022 | December 2023 | Allow | 20 | 1 | 0 | No | No |
| 17708960 | COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS | March 2022 | September 2023 | Allow | 17 | 1 | 0 | No | No |
| 17707192 | CROSSLINKABLE COATING COMPOSITIONS FORMULATED WITH DORMANT CARBAMATE INITIATOR | March 2022 | July 2023 | Allow | 16 | 1 | 0 | No | No |
| 17687754 | ICARIIN NANO-PHARMACEUTICAL FORMULATION | March 2022 | August 2022 | Allow | 6 | 1 | 1 | No | No |
| 17688676 | METHOD AND DEVICE FOR IN VIVO BRONCHUS REGENERATION | March 2022 | June 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17640620 | FOOD COMPOSITIONS FOR LACTATING WOMEN | March 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17675043 | CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE | February 2022 | July 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17675605 | MELT PROCESSED VIRAL NANOPARTICLE CONSTRUCTS | February 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17673672 | Systems and Methods for Generating and Applying Biomimicry Tear Films | February 2022 | June 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17671447 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | February 2022 | September 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17666727 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | February 2022 | January 2024 | Allow | 23 | 2 | 0 | No | No |
| 17666846 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | February 2022 | August 2024 | Allow | 31 | 3 | 0 | Yes | No |
| 17666802 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | February 2022 | February 2024 | Allow | 24 | 2 | 0 | No | No |
| 17666760 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | February 2022 | January 2024 | Allow | 24 | 2 | 0 | No | No |
| 17666714 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | February 2022 | January 2024 | Allow | 23 | 2 | 0 | No | No |
| 17666783 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | February 2022 | February 2024 | Allow | 24 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TRUONG, QUANGLONG N.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner TRUONG, QUANGLONG N works in Art Unit 1615 and has examined 581 patent applications in our dataset. With an allowance rate of 77.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.
Examiner TRUONG, QUANGLONG N's allowance rate of 77.5% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by TRUONG, QUANGLONG N receive 1.80 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by TRUONG, QUANGLONG N is 23 months. This places the examiner in the 74% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +22.4% benefit to allowance rate for applications examined by TRUONG, QUANGLONG N. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 32.2% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 31.2% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 50.4% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.